{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Steroid+treatment&page=51", "query": { "intervention": "Steroid treatment", "page": 51 }, "page_size": 10 }, "pagination": { "page": 51, "page_size": 10, "total_count": 4086, "total_pages": 409, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Steroid+treatment&page=52&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Steroid+treatment&page=50&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T13:44:34.095Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05322070", "title": "Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Uveitis, Posterior" ], "interventions": [ { "name": "Fluocinolone Acetonide Intravitreal Implant 0.18 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alimera Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2022-06-06", "completion_date": "2025-11", "has_results": false, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-10-17T13:44:34.095Z", "location_count": 23, "location_summary": "Fullerton, California • Glendale, California • Pasadena, California + 20 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Lakewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05322070" }, { "nct_id": "NCT03314181", "title": "A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2018-04-02", "completion_date": "2031-05", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-10-17T13:44:34.095Z", "location_count": 14, "location_summary": "Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03314181" }, { "nct_id": "NCT00814255", "title": "Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Focal Segmental Glomerulosclerosis" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Lisinopril, losartan, and atorvastatin", "type": "DRUG" }, { "name": "galactose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "65 Years", "sex": "ALL", "summary": "1 Year to 65 Years" }, "enrollment_count": 32, "start_date": "2008-12", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2016-07-11", "last_synced_at": "2026-10-17T13:44:34.095Z", "location_count": 17, "location_summary": "Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00814255" }, { "nct_id": "NCT04760691", "title": "Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV", "Prophylaxis", "Transgender" ], "interventions": [ { "name": "Truvada alone", "type": "DRUG" }, { "name": "Truvada plus Leuprolide 11.25mg intramuscular injection", "type": "DRUG" }, { "name": "Truvada plus Estradiol 1 mg", "type": "DRUG" }, { "name": "Truvada plus Estradiol 6 mg", "type": "DRUG" }, { "name": "Estradiol 6 mg alone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 13, "start_date": "2021-03-01", "completion_date": "2025-03-24", "has_results": true, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-17T13:44:34.095Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04760691" }, { "nct_id": "NCT03548246", "title": "Androgen Reduction in Congenital Adrenal Hyperplasia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Congenital Adrenal Hyperplasia" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Fludrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "9 Years", "sex": "ALL", "summary": "2 Years to 9 Years" }, "enrollment_count": 0, "start_date": "2023-01", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2023-02-01", "last_synced_at": "2026-10-17T13:44:34.095Z", "location_count": 4, "location_summary": "Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03548246" }, { "nct_id": "NCT04181827", "title": "A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cilta-cel", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 419, "start_date": "2020-06-12", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-17T13:44:34.095Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04181827" }, { "nct_id": "NCT06099769", "title": "A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Mifepristone", "type": "DRUG" }, { "name": "TPC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2023-10-18", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-10-17T13:44:34.095Z", "location_count": 12, "location_summary": "Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06099769" }, { "nct_id": "NCT02528383", "title": "Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Vagifem", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Susan Tannenbaum", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2015-08", "completion_date": "2017-05", "has_results": false, "last_update_posted_date": "2017-09-18", "last_synced_at": "2026-10-17T13:44:34.095Z", "location_count": 1, "location_summary": "Farmington, Connecticut", "locations": [ { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02528383" }, { "nct_id": "NCT03532022", "title": "Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Congenital Adrenal Hyperplasia" ], "interventions": [ { "name": "Chronocort®", "type": "DRUG" }, { "name": "Standard Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neurocrine UK Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 0, "start_date": "2018-10-04", "completion_date": "2021-07-09", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-17T13:44:34.095Z", "location_count": 1, "location_summary": "Morehead City, North Carolina", "locations": [ { "city": "Morehead City", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03532022" }, { "nct_id": "NCT03089853", "title": "Smart Telehealth Exercise Intervention to Reduce COPD Readmissions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Neuromuscular electrical stimulation (NMES)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 7, "start_date": "2016-07-14", "completion_date": "2020-08-15", "has_results": true, "last_update_posted_date": "2022-03-22", "last_synced_at": "2026-10-17T13:44:34.095Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03089853" } ] }